Bergqvist M, et al. - Among stage IIIB-IV non-small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR) targeting tyrosine kinase inhibitors (TKIs), researchers analyzed time trends in treatment pattern and prognostic issues for overall survival (OS), utilizing Swedish nationwide registers. Participants were observed from diagnosis (2010-2015) until death or end of observation (2016). An improvement in the survival during follow-up as well as in the accessibility for targeted therapies was reported for EGFR TKI treated NSCLC patients. Among participants, younger age, adenocarcinoma, less advanced clinical stage, and less comorbid disease were identified as prognostic factors for longer OS.